EUCTR2004-005085-21-GB进行中（未招募）1 期
Scalp lotion for the treatment of pityriasis capitis (severe dandruff) and seborrhoeic dermatitis. - Pityriasis capitis scalp lotion trial.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Aged 18 years and above presenting with pityriasis capitis. Pityriasis capitis (severe dandruff) is defined, for study purposes, as having a history of scalp itching and dandruff for a minimum of the previous two months, and having, on examination, diffuse or patchy scaling areas of the scalp with or without accompanying erythema and which is clearly not psoriasis. A global severity rating of at least 8 (maximum score 20). Patients willing to refrain from using any other treatments and prepared to use only the study shampoo and Johnson's Baby shampoo for their scalp for the duration of the study.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •i) Patients with excoriated/broken skin on their scalp.
- •ii) Patients with a history of intolerance or skin sensitivity to any of the ingredients of the investigational shampoos and lotions.
- •iii) Patients with a history of intolerance or skin sensitivity to any of the ingredients of Johnson's Baby shampoo.
- •iv) Patients who have received systemic treatment for any dermatosis in the previous 2 weeks.
- •v) Patients who have used steroids for their scalp condition within the previous 4 weeks.
- •vi) Patients who have received any unlicensed drug within the last 30 days or who are scheduled to receive an investigative drug other than the study medication during the period of the study.
- •vii) Patients with systemic diseases which, in the opinion ofthe investigator, may adversely influence their participation in the trial.
- •viii) Patients who are pregnant or lactating (although there are no particular safety concerns in these patient groups, it is generally inappropriate for them to participate in clinical trials without overriding justification).
- •ix) Patients considered unable or unlikely to attend the necessary follow-up visits.
- •x) Patients who are immunocompromised or taking immunosuppresants.
- •xi) Patients with psoriasis, discoid lupus erythematosus or lichen simplex chronicus.
研究者
相似试验
已完成
3 期
Treatment of pityriasis rosea, a skin rash, with antiviral drug acyclovirCTRI/2012/09/002995KLM Laboratories Pvt Ltd Provided acyclovir tablets and placebo tablets only30
已完成
不适用
Turmeric tonic in the management of scalp psoriasis; a clinical double blind, placebo controlled evaluatioPsoriasis.PsoriasisIRCT201604183106N30Islamic Azad University Pharmaceutical branch and Self supported40
进行中（未招募）
不适用
ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.Psoriasis of the scalpExtent: Minimum 10% of the total scalp areaDisease severity: Graded as moderate, severe, or very severe according to the investigator's global assessment of disease severityClinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbsMedDRA version: 7.0Level: LLTClassification code 10037115EUCTR2004-002861-19-GBEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)800
进行中（未招募）
1 期
ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.EUCTR2004-002861-19-DKEO Pharma A/S800
进行中（未招募）
不适用
ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.Psoriasis of the scalpExtent: Minimum 10% of the total scalp areaDisease severity: Graded as moderate, severe, or very severe according to the investigator's global assessment of disease severityClinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbsMedDRA version: 7.0Level: LLTClassification code 10037115EUCTR2004-002861-19-DEEO Pharma A/S800